Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 8,496	$ 20,549
Short-term investments	116,385	119,629
Prepaid expenses and other current assets	2,837	3,552
Total current assets	127,718	143,730
Operating lease asset, net	850	926
In-process research and development	32,386	32,386
Other assets	354	363
Total assets	161,308	177,405
Current liabilities:
Accounts payable	2,901	5,833
Current operating lease liabilities	325	314
Accrued expenses and other liabilities	5,959	5,430
Total current liabilities	9,185	11,577
Deferred tax liabilities	2,183	2,183
Non-current operating lease liabilities	555	640
Warrant liabilities	34,805	44,865
Total liabilities	46,728	59,265
Commitments and contingencies (Note 7)
Stockholders' equity:
Common stock, $0.001 par value, 200,000,000 shares authorized at March 31, 2025 and December 31, 2024; 59,881,775 and 59,789,275 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	60	60
Additional paid-in capital	476,619	473,640
Accumulated other comprehensive income (loss)	(18)	26
Accumulated deficit	(362,081)	(355,586)
Total stockholders’ equity	114,580	118,140
Total liabilities and stockholders' equity	161,308	177,405
Series X1 Non-voting Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value
Series X Non-Voting Convertible Preferred Stock [Member]
Stockholders' equity:
Preferred stock, value

In-process research and development.

No definition available.

Name:	eldn_InProcessResearchAndDevelopment
Namespace Prefix:	eldn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).